Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Veru Inc. (VERU:NASDAQ), powered by AI.
Veru Inc. is currently trading at $4.23. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Veru Inc. on Alpha Lenz.
Veru Inc.'s P/E ratio is -2.7.
“Veru Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -89.7%.”
Ask for details →Veru Inc., a biopharmaceutical company, is focused on developing and commercializing novel medicines for the management of oncology and infectious diseases. The primary aim of Veru is to address the unmet needs in oncology treatment, particularly focusing on prostate cancer, breast cancer, and other tumor types. With its innovative approach, Veru Inc. impacts the healthcare and pharmaceutical sectors by offering new therapeutic solutions that can potentially improve patient outcomes. The company is also actively engaged in the development of treatments for infectious diseases, leveraging its expertise in drug development to expand its portfolio. Based in Miami, Florida, Veru Inc. plays a significant role in the biopharmaceutical industry, contributing to both clinical advancements and the proliferation of healthcare options. The company's pipeline includes both proprietary pharmaceuticals and those acquired or licensed for development, emphasizing the significance of strategic partnerships in enhancing its R&D capabilities.
“Veru Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -89.7%.”
Ask for details →Veru Inc. (ticker: VERU) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 210 employees. Market cap is $62M.
The current price is $4.23 with a P/E ratio of -2.73x and P/B of 3.38x.
ROE is -89.74%.